Key statistics
On Friday, INmune Bio Inc (INMB:NAQ) closed at 1.44, 4.35% above its 52-week low of 1.38, set on Nov 14, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.48 |
|---|---|
| High | 1.51 |
| Low | 1.43 |
| Bid | 1.45 |
| Offer | 1.50 |
| Previous close | 1.47 |
| Average volume | 306.92k |
|---|---|
| Shares outstanding | 26.59m |
| Free float | 22.06m |
| P/E (TTM) | -- |
| Market cap | 38.28m USD |
| EPS (TTM) | -2.14 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
- INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
- INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
- Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
- INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
- INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
- INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
- INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
- INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
- INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
More ▼
